TScan Therapeutics
IPO
- Headquarters
- Waltham, Massachusetts
- Employees
- 51–200
- Founded
- 2018
- Business Model
- B2B
- Website
- ir.tscan.com
- Total Funding
- $190.0M
- Last Round
- $30.0M Corporate RoundDec 2024
About
Clinical-stage biotechnology company developing T cell receptor (TCR)-engineered T cell therapies for cancer and autoimmune diseases.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free Account